Autoimmunity to glutamic acid decarboxylase
(GAD) in stiff-man syndrome and insulin-dependent diabetes mellitus.
UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase
for prediction of insulin requirement in type 2 diabetes.
The diabetic antigen glutamic acid decarboxylase
(GAD 65) in the human peripheral blood.
A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase
antibodies in childhood IDDM.
Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase
disciminate two clinically distinct types of latent autoimmune diabetes in adults (LADA).
Quantitative assay using recombinant human islet glutamic acid decarboxylase
(GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type.
High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase
Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase
65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus.
The researchers' findings prove that masking or hiding the foreign nature of the affected cells, in particular a protein named glutamic acid decarboxylase
or GAD, from the immune system could prevent the immunological process that causes diabetes.
The gene encodes glutamic acid decarboxylase
(GAD), an enzyme which synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA).
The most important markers for [beta]-cell autoimmunity are autoantibodies against insulin (40, 41), glutamic acid decarboxylase
(GAD65) (41, 42), and islet cell antigen-2 (IA-2) (41, 43, 44).
Nasdaq: GZTC) announced today that it has successfully expressed high levels of glutamic acid decarboxylase
(GAD), a protein that is a potential therapy for insulin-dependent diabetes mellitus (type 1 diabetes), in the milk of transgenic mice.